Next Article in Journal
Chromothripsis—Explosion in Genetic Science
Previous Article in Journal
Glycosylation of Immune Receptors in Cancer
Open AccessArticle

HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells

1
Department of Microbiology & Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON N6G 2V4, Canada
2
Department of Biochemistry, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON N6G 2V4, Canada
*
Author to whom correspondence should be addressed.
Academic Editor: Ryan Mailloux
Cells 2021, 10(5), 1101; https://doi.org/10.3390/cells10051101
Received: 13 April 2021 / Revised: 29 April 2021 / Accepted: 30 April 2021 / Published: 4 May 2021
(This article belongs to the Special Issue Cell Biology: State-of-the-Art and Perspectives in Canada)
Inhibition of the RAF-MEK1/2-ERK signaling pathway is an ideal strategy for treating cancers with NRAS or BRAF mutations. However, the development of resistance due to incomplete inhibition of the pathway and activation of compensatory cell proliferation pathways is a major impediment of the targeted therapy. The anthrax lethal toxin (LT), which cleaves and inactivates MEKs, is a modifiable biomolecule that can be delivered selectively to tumor cells and potently kills various tumor cells. However, resistance to LT and the mechanism involved are yet to be explored. Here, we show that LT, through inhibiting MEK1/2-ERK activation, inhibits the proliferation of cancer cells with NRAS/BRAF mutations. Among them, the human colorectal tumor HT-29 and murine melanoma B16-BL6 cells developed resistance to LT in 2 to 3 days of treatment. These resistant cells activated AKT through a histone deacetylase (HDAC) 8-dependent pathway. Using an Affymetrix microarray, followed by qPCR validation, we identified that the differential expression of the phospholipase C-β1 (PLCB1) and squamous cell carcinoma-1 (DESC1) played an important role in HDAC8-mediated AKT activation and resistance to MEK1/2-ERK inhibition. By using inhibitors, small interference RNAs and/or expression vectors, we found that the inhibition of HDAC8 suppressed PLCB1 expression and induced DESC1 expression in the resistant cells, which led to the inhibition of AKT and re-sensitization to LT and MEK1/2 inhibition. These results suggest that targeting PLCB1 and DESC1 is a novel strategy for inhibiting the resistance to MEK1/2 inhibition. View Full-Text
Keywords: lethal toxin; AKT; PLCB1; PI-PLC; DESC1; HT-29 cells; cancer; resistance lethal toxin; AKT; PLCB1; PI-PLC; DESC1; HT-29 cells; cancer; resistance
Show Figures

Figure 1

MDPI and ACS Style

Ha, S.-D.; Lewin, N.; Li, S.S.C.; Kim, S.-O. HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells. Cells 2021, 10, 1101. https://doi.org/10.3390/cells10051101

AMA Style

Ha S-D, Lewin N, Li SSC, Kim S-O. HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells. Cells. 2021; 10(5):1101. https://doi.org/10.3390/cells10051101

Chicago/Turabian Style

Ha, Soon-Duck; Lewin, Naomi; Li, Shawn S.C.; Kim, Sung-Ouk. 2021. "HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells" Cells 10, no. 5: 1101. https://doi.org/10.3390/cells10051101

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop